- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Ultrasound-guided injections control recurrent papillary thyroid carcinoma
Ultrasound-guided percutaneous ethanol injections hold up as a treatment for controlling neck recurrence of papillary thyroid carcinoma. They could be effective for patients who are poor candidates for surgery.
Ultrasound-guided percutaneous ethanol injections hold up as a treatment for controlling neck recurrence of papillary thyroid carcinoma. They could be effective for patients who are poor candidates for surgery.
Standard treatment for the recurrence of papillary thyroid carcinoma in the neck requires surgery, and early surgical treatment improves prognosis for a recurring neck papillary thyroid carcinoma. But not all patients can tolerate surgery or radioactive iodine therapy when the recurrence of their cancer is found.
Dr. Byung Moon Kim in the radiology department at Sungkyunkwan University School of Medicine, Kangbuk Samsung Hospital and colleagues at other hospitals in Seoul published their study in European Radiology, which made it available online Nov. 27.
They studied 47 recurring neck papillary thyroid carcinomas in 27 patients between 19 and 80 years old, with a mean age of 53.2. All patients received treatments consisting of repeated ultrasound-guided percutaneous injections of 99% ethanol, with the needle position adjusted until the entire volume of papillary thyroid carcinoma was ablated. Follow-up ultrasound exams at three to six month intervals measured the percent volume decrease.
Treatment was considered effective when the papillary carcinoma decreased in volume and a power Doppler ultrasound exam showed no tumor vascularity. Failed treatments were those in which the carcinoma volume increased, remained stable, or showed tumor vascularity. Those treatments were repeated in additional sessions.
The researchers tracked the number of sessions and the total volume of ethanol per carcinoma. By the end of the study, all tumors had decreased significantly in volume. Decreases ranged from 30% to 100%, with a mean of 93.6%. The mean number of sessions per carcinoma was 2.1, ranging from one to six. The mean volume of ethanol used was 1.1 mL/session, ranging from 0.3 to 3 mL per session, and the mean total volume of ethanol per carcinoma was 2.4 mL, ranging from 0.3 to 10.1 mL.
The researchers concluded that ultrasound-guided percutaneous ethanol injection could be used as a treatment for neck recurring papillary thyroid carcinomas. This option would open up another treatment for those patients who couldn't tolerate surgery.
MRI or Ultrasound for Evaluating Pelvic Endometriosis?: Seven Takeaways from a New Literature Review
September 13th 2024While noting the strength of MRI for complete staging of disease and ultrasound’s ability to provide local disease characterization, the authors of a new literature review suggest the two modalities offer comparable results for diagnosing pelvic endometriosis.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Controlled Contrast Delivery Method for Ultrasound Imaging of Fallopian Tubes
September 9th 2024Facilitating natural contrast delivery through an intrauterine catheter, FemChec can be utilized for ultrasound assessment of fallopian tubes and may provide diagnostic confirmation for an emerging non-surgical option for permanent birth control.
FDA Clears Emerging Cardiovascular Point-of-Care Ultrasound Platform
August 22nd 2024Combining four CAD modules for valvular pathologies with a variety of automated measurements, the AI-enabled AISAP Cardio ultrasound system reportedly facilitates up to a 90 percent accuracy rate in detecting common cardiac conditions.
Predicting DCIS Upgrade to Invasive Breast Cancer: Can Contrast-Enhanced Ultrasound Have an Impact?
August 21st 2024Adding two key findings from contrast-enhanced ultrasound to a predictive model of mammography, conventional ultrasound and clinicopathological findings led to a 86.1 percent AUROC for predicting the upgrading of ductal carcinoma in situ to invasive breast cancer, according to new research.
